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Charlotte M. Niemeyer4,5,6, Rami N. Khoriaty12, Philip Ancliff7, Hanna T. Gazda2,13, Marcin W. Wlodarski4,5,6, and Vijay G. Sankaran1,2
Studies of allelic variation underlying genetic blood disorders have provided important insights into human hematopoiesis.
Most often, the identified pathogenic mutations result in loss-of-function or missense changes. However, assessing the
pathogenicity of noncoding variants can be challenging. Here, we characterize two unrelated patients with a distinct
presentation of dyserythropoietic anemia and other impairments in hematopoiesis associated with an intronic mutation in
GATA1 that is 24 nucleotides upstream of the canonical splice acceptor site. Functional studies demonstrate that this single-
nucleotide alteration leads to reduced canonical splicing and increased use of an alternative splice acceptor site that causes a
partial intron retention event. The resultant altered GATA1 contains a five–amino acid insertion at the C-terminus of the
C-terminal zinc finger and has no observable activity. Collectively, our results demonstrate how altered splicing of GATA1, which
reduces levels of the normal form of this master transcription factor, can result in distinct changes in human hematopoiesis.
Introduction
While hematopoiesis is arguably one of the best-understood
paradigms of cellular differentiation in physiology, many fac-
ets of this process remain to be characterized. Genetic blood
disorders provide an opportunity to learn more about hemato-
poiesis, even in cases where the mutated gene has been previ-
ously well studied, since allelic variation can provide novel
biological insights (Casanova et al., 2014; Basak et al., 2015;
Kuehn et al., 2016; Polfus et al., 2016; Kim et al., 2017; Zmajkovic
et al., 2018). Advances in sequencing technologies have enabled
rapid and efficient mutation identification, but deciphering the
pathogenicity of noncoding variation can be immensely chal-
lenging. Noncoding transcriptional regulatory elements can be
interrogated using a number of functional approaches, including
the use of genome editing and exogenous assays of regulatory
function (Ulirsch et al., 2016; Wakabayashi et al., 2016; Gasperini
et al., 2017). However, deciphering the pathogenicity of cryptic
splicingmutations can present substantial challenges (Rosenberg
et al., 2015; Cummings et al., 2017).
Here we have identified two unrelated patients with a unique
form of dyserythropoietic anemia that is associated with other
abnormalities in hematopoiesis. Both of the patients harbor
identical intronic mutations in GATA1. Through functional
studies, we show that this single-nucleotide change leads to al-
tered splice acceptor usage, along with a decrease in canonical
GATA1 splicing and expression, thereby resulting in the disease
phenotype. This mutation disrupts the activity of the U2 splicing
complex in the last intron of GATA1. While this complex is also
mutated in more commonly observed cases of myelodysplastic
syndrome (MDS), which can be attributable to somatic muta-
tions in this splicing regulatory complex itself (Yoshida et al.,
2011; Sperling et al., 2017), we were not able to identify a con-
nection between the altered splicing observed in these two cases
of dyserythropoietic anemia and more common cases of MDS.
Nonetheless, our study illustrates how decreasing the splicing
efficiency of the hematopoietic master regulator GATA1 can
impair selective aspects of human hematopoiesis and lead to
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distinct phenotypes in comparison with other pathogenic mu-
tations affecting the same gene (Sankaran et al., 2012; Campbell
et al., 2013; Crispino and Horwitz, 2017).
Results and discussion
In the course of studying a cohort of patients with rare genetic
blood disorders, we encountered two patients who both had a
distinct form of dyserythropoietic anemia that necessitated
transfusions in the intrauterine period and/or in early infancy
with subsequent evolution into a milder anemia that was noted
to worsen in the setting of intercurrent illnesses. Bone marrow
evaluation of the patients revealed moderate dyserythropoiesis,
along with frequent, small hypolobated megakaryocytes and
occasional dysplastic myeloid cells (Figs. 1 A and S1 A). Platelet
function testing in patient 1, who was noted to have clinical
bleeding, revealed specific impairments, including defective
aggregation and α-/δ-granule secretion (as indicated by de-
creased expression of P-selectin/CD62 and LAMP-3/CD63),
which are suggestive of defective thrombopoiesis (Figs. 1 B and
S1 B). Patient 2 was also noted to have abnormal platelet function
testing. Further clinical details of the two patients are described
in Materials and methods. To assess the etiology of the impaired
hematopoiesis in these patients, whole-exome sequencing
(WES) and targeted mutation analysis were performed. No
known blood disorder–associated mutations were identified
(Materials and methods), but both patients were noted to have a
unique mutation in the fifth intron of GATA1 (chrX:48,652,176
C>T in hg19) that was carried in the mothers of these patients
(Figs. 1 C and S1 C). This mutation was absent from the 123,136
exomes and 15,496 genomes in the gnomAD database, despite
excellent coverage of this region (Materials and methods).
The identified mutation was located 24 nucleotides upstream
of the canonical splice acceptor site in the fifth intron of GATA1.
While the mutation was not predicted to disrupt known splicing
elements, we hypothesized that it may impair appropriate
splicing of this gene. To directly interrogate this, we used a
minigene reporter assay (Fig. 2, A and B; Kishore et al., 2008).
We found that the mutation reduced normal splicing of this
region of GATA1 and promoted an intron retention event of 15
nucleotides involving an alternative splice acceptor site (Fig. 2
B). Semiquantitative RT-PCR analysis revealed a reduction of
canonical GATA1 splicing to 42% of normal levels, with the mu-
tant mRNA at 36% of normal levels (Fig. 2 C). Importantly, we
Figure 1. Identification of a GATA1 intronic mutation in two unrelated patients with dyserythropoietic anemia. (A) Images of bone marrow aspirates
from patients 1 and 2 are shown as images taken with 40× and 60× objectives, respectively. Notable features in both patients include mild to moderate
dyserythropoiesis and other alterations, including hypolobated dysplastic megakaryocytes. (B) The thrombin-induced expression of CD62 and CD63 on
platelets from patient 1 or a healthy control was detected by flow cytometry (shown as a percentage). There is defective expression of these antigens, in-
dicating an α-/δ-granule deficiency. (C) Sequencing chromatograms of mutation in GATA1 (chrX:48,652,176 C>T in hg19) from a healthy control, the two
patients, and their mothers. Scale bars: 10 µm.
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could confirm that this altered splicing was present in the pa-
tient samples but was found at significantly lower levels in
healthy controls (Figs. 2 D and 3, A and B). By sequencing, we
confirmed that the patients had an identical intron retention
event of the same 15 nucleotides noted in the minigene assay.
We did not identify any major variation in GATA1 splicing over
the course of erythroid differentiation of primary adult CD34+
hematopoietic stem and progenitor cells (HSPCs; Hu et al., 2013;
Ulirsch et al., 2016; Figs. 2 E and 3), suggesting that the signifi-
cantly altered splicing observed in these cases was attributable
to the distinctive pathogenic variants. Importantly, we note that
this altered splice variant is found in only 1.9–4.6% of GATA1
transcripts during normal human erythropoiesis, emphasizing
its minor contribution to total GATA1 mRNA levels (Fig. 3 B).
We next wanted to further investigate the underlying
mechanisms for the altered splicing present due to these path-
ogenic mutations. Interestingly, the observed alternative splice
acceptor site usage with resultant intron retention (Fig. 2 F) was
similar to what is frequently observed in SF3B1-mutated MDS,
where there is alternative splice acceptor site usage in a number
of transcripts between ∼15 and 25 nucleotides upstream of the
canonical splice acceptor site (DeBoever et al., 2015; Obeng et al.,
2016). Given the phenotypic similarity between MDS and the
disordered hematopoiesis observed in these patients, as well as
Figure 2. Decreased canonical splicing and intron retention due to a pathogenic GATA1mutation. (A) Schematic of the minigene assay involving exons 5
and 6 and the intervening intron of GATA1. The minigene vector, pSpliceExpress, includes two exons from rat insulin (Rat Ins Ex) as a control for splicing, a SV-
40 promoter (Prom), and a polyadenylation site (PolyA). (B) Representative RT-PCR from the minigene assay in the presence or absence of the mutation shows
the reduction of canonical splicing and presence of an intron retention event, which was confirmed through cloning and Sanger sequencing of the resultant
products. (C) Semiquantitative RT-PCR analysis of the minigene assay using 28, 30, 32, and 34 PCR cycles. The bar graph (below) depicts quantified levels of the
various products, including the total amount of GATA1 (red), the amount of the wild-type band (blue), or the amount of the mutant (Mut) band in the setting of
the mutation involving an intron retention event (***, P < 0.001; n = 4). (D) RT-PCR analysis of GATA1 exon 5 and exon 6 from control and patient peripheral
blood mononuclear cells. (E) Representative RT-PCR analysis of GATA1 exons 5 and 6 from human HSPCs undergoing erythroid differentiation. (F) Schematic
demonstrating alternative splicing in the fifth intron of GATA1, including the location of the intronic mutation and the nucleotides involved in intron retention
(red). The splicing patterns are depicted above with a red dashed (alternative) or solid black (canonical) line. (G) RT-PCR analysis of the minigene assay
performed as above or with increased expression of wild-type SF3B1 or the K700E SF3B1 mutated protein in 293T cells.
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the likely involvement of the U2 splicing complex in the region
where this mutation resided, we tested whether the commonly
observed SF3B1 K700Emutant, which alters U2 splicing activity,
would further diminish the observed altered splicing due to this
intronic GATA1 mutation. Using the minigene assay described
above, we found that expression of the SF3B1 K700E mutant
markedly impaired canonical splicing of the mutant GATA1 and
led to near-complete alternative splice acceptor usage (Fig. 2 G).
This finding suggests that the observed germline mutation in
these patients specifically alters the activity of the U2 splicing
complex in this region of GATA1. Given the involvement of this
complex in MDS, we examined whether SF3B1-mutated MDS
cases (with a diagnosis of refractory anemia with ringed side-
roblasts) may have altered splicing or levels of GATA1, but we
did not observe consistent defects, suggesting altered splicing
or the presence of reduced levels of GATA1 mRNA, even in
sorted stage-matched bone marrow populations (Fig. S2). This
finding is not surprising, given the minimal effect of the SF3B1
K700E mutation on splicing of the wild-type form of GATA1 in
the minigene assay discussed above (Fig. 2 G). Nonetheless,
given the phenotypic and molecular connections, we felt it
worthwhile to explore possible connections between these
conditions.
To gain further insight into the mechanism by which the
GATA1 intronic mutant disrupts human hematopoiesis, we ex-
amined whether the protein produced from the intron retention
event—which would add five additional amino acids at the
C-terminus of the C-terminal zinc finger of GATA1—may have
altered activity (Fig. 4 A). In human embryonic kidney
293T cells, we found that both RNA levels (as inferred through
the expression of a linked GFP molecule that is translated from
an internal ribosome entry site on the same transcript and
through direct measurement) and protein levels (as measured
directly) of this mutated cDNAwere stable and similar to what is
observed with wild-type GATA1 cDNA (Fig. 4, B and C). More-
over, in the mouse Gata1-null erythroid cell line, G1E, we found
similar expression of the mutated and wild-type proteins
(Fig. 4 D). Exogenous expression of the mutated cDNA in pri-
mary HSPCs induced to undergo erythroid differentiation re-
vealed that the mutated form had little effect on promoting
precocious erythroid differentiation, as occurs with the wild-
type cDNA, and importantly there was no dominant-negative
activity observed in this setting where wild-type GATA1
protein is present (Fig. 4 E; Ludwig et al., 2014; Giani et al.,
2016; Wakabayashi et al., 2016). To directly assess whether the
protein formed by this mutation is inactive or hypomorphic,
Figure 3. Rare intron retention events during physiological human erythroid differentiation. (A) Sashimi plots showing splicing events in the GATA1
locus across the indicated stages of human erythropoiesis as determined by RNA-seq analysis. (B) Quantification of rare events of intron retention at indicated
stages as counts of junction-spanning reads with the percentage of total transcript reads this represents shown in parentheses. Alternate and canonical splice
acceptors are highlighted in pink. One representative example shown per stage of erythropoiesis.
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Figure 4. GATA1 variant produced through the intron retention event is stably expressed, but shows no function. (A) Schematic shows insertion of five
amino acids as a result of the intron retention event. (B) A histogram plot (left) shows GFP levels indicating robust expression and equivalent transfection
efficiency (GFP linked to GATA1 cDNA by internal ribosomal entry site). Mutant and wild-type GATA1 mRNA are expressed at equivalent levels (right). (C) A
representative Western blot of GATA1 levels from exogenous cDNA expression in 293T cells. Loading control is GAPDH. (D)Western blot of GATA1 levels from
exogenous cDNA expression in erythroid G1E cells (three biological replicates per indicated construct). Loading control is GAPDH. (E) Representative flow
cytometric assessment (of three replicates) of erythroid differentiation (using CD235a, CD71, and CD49d surface markers) on day 7 and day 12 of culture of
human HSPCs upon exogenous expression of wild-type GATA1 or the GATA1 mutant protein. (F) Representative histogram plots (of three replicates) assessing
the marker of mouse erythroid differentiation, Ter119, in G1E cells infected with the empty vector (control), GATA1 wild type, or GATA1 mutant cDNAs vectors
after 48, 72, or 96 h.
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we used the G1E Gata1-null cell line, to complement this
phenotype with either the wild-type or mutant cDNAs (Rylski
et al., 2003; Campbell et al., 2013). While the wild-type cDNA
robustly promoted erythroid differentiation in this setting
based on Ter119 marker induction, the mutant form failed to
do so, suggesting that this mutated protein produced from an
intron retention event may result in loss of function (Figs. 4 F
and S3).
To globally assess the potentially altered transcriptional ac-
tivity of the mutant splice variant of GATA1, we infected G1E
cells with either the wild-type or mutant cDNA and conducted
RNA sequencing (RNA-seq) 72 h after infection. While wild-type
GATA1 either activated or repressed a large number of canonical
target genes (Fig. 5, A, E, and F), expression of the mutant form
had little change compared with the control lentivirus (Fig. 5, B,
E, and F). Importantly, expression of the cDNAs was at compa-
rable levels (Fig. 5, C and D). Interestingly, we did note some
subtle repression of select GATA1-repressed genes by the mu-
tant form (cluster K3, Fig. 5 F). To investigate this further, we
assessed GATA1 chromatin occupancy near the transcription
start sites (TSSs) of these genes as measured by chromatin im-
munoprecipitation sequencing (ChIP-seq; ENCODE Project
Consortium, 2012) but noted very little occupancy in this set
of genes, in contrast to the majority of GATA1 activated genes
(Fig. 5, F and G, cluster K1 vs. K3). Together with the data shown
above from the interrogation of splicing, these results demon-
strate that the impaired hematopoiesis in these cases emerges
due to reduced expression of wild-type GATA1 to ∼40% of
normal levels with the production of an inactive mutant protein
due to an intron retention event.
Our findings have several important and broad implications.
While determining the functional consequences of cryptic
splicing mutations can be challenging, we illustrate how by
using a series of functional assays, the mechanisms underlying
such mutations can be more fully understood. Exactly how the
activity of the U2 splicing complex is altered in these cases re-
mains uncertain, but given the lack of consensus binding se-
quences, no clear-cut mechanisms have been apparent. Given
the finding of interactions between a mutant form of SF3B1
commonly observed inMDS cases and the germlinemutationwe
identified, as well as the phenotypic similarity between these
disorders, it is interesting to speculate about potential con-
nections between these observations. However, we have not
been able to demonstrate aberrant GATA1 mRNA splicing or
expression in MDS cases in our analyses, but given the pheno-
typic similarities between this form of dyserythropoietic anemia
and MDS, the reported perturbation of GATA1 protein levels in
MDS patient samples (Frisan et al., 2012), and the myelodys-
plasia seen inmousemodels with reduced Gata1 levels (McDevitt
et al., 1997; Takahashi et al., 1998), this will be an important area
for further investigation in the future.
Our findings also demonstrate how by reducing the overall
levels of GATA1, a distinct defect in human hematopoiesis can
emerge. Importantly, the observed hematologic phenotype in
the two patients described here is different from other cases of
GATA1-mutated blood phenotypes. Missense mutations in GATA1
can result in other forms of dyserythropoiesis, thalassemia, and
a variety of thrombopoietic defects (Crispino and Horwitz,
2017). Lack of the full-length form of GATA1 with continued
production of the short isoform can cause Diamond-Blackfan
anemia (DBA; Sankaran et al., 2012). We have recently found
that impaired translation of GATA1 in early hematopoietic
progenitors underlies the most commonly observed cases of
DBA due to ribosomal protein mutations (Ludwig et al., 2014;
Khajuria et al., 2018). Moreover, such aberrant translation of
GATA1 may also occur in other blood disorders, such as myelo-
fibrosis (Gilles et al., 2017). The results we describe in this paper
extend the spectrum of GATA1-related disease and show how
distinct alleles in a single key regulator of hematopoiesis can
cause pleiotropic phenotypes, illuminating the numerous func-
tions of GATA1 in human hematopoiesis.
Materials and methods
Patients and family
Patient 1 was a boy born at full term to healthy unrelated parents
from Bulgaria (mother) and Togo (father). On the first day of
life, anemia with a hemoglobin (Hb) of 9.4 g/dL and concomitant
jaundice with elevated lactate dehydrogenase were noted. Be-
sides second-degree hypospadias, no syndromic features were
present. The patient required transfusions at 6 wk and 3 mo of
age because of Hb decreases to the 5-g/dL range with an inad-
equate reticulocyte response and lower gastrointestinal bleed-
ing. Subsequently, the child maintained a stable Hb of 8–10 g/dL
with persistent red cell macrocytosis and a few giant platelets. At
the age of 3.5 yr, a respiratory tract infectionwith febrile seizure
occurred with transiently worsened anemia (Hb 6.3 g/dL, re-
ticulocytes at 18%) and a mild thrombocytopenia (133,000 cells/
µl). The patient had an elevated lactate dehydrogenase with no
signs of active hemolysis. Extensive evaluations performed
during and between the acute episodes for nonimmune hemo-
lytic anemias; infectious, metabolic, and autoimmune disorders;
and bone marrow failure syndromes (including mitomycin
C–induced DNA damage testing and telomere length measure-
ments) were unrevealing. An erythrocyte adenosine deami-
nase level was elevated at 2.79 U/g Hb. Multiple bone marrow
examinations revealed normal cellularity with signs of dysery-
thropoiesis with macrocytic and occasional megaloblastic dif-
ferentiation, mild dysplasia of the megakaryocytic lineage with
hypolobated forms, and hypogranulated neutrophils. During
infection-free periods, the Hb remained stable at levels of
9–10 g/dl with macrocytosis (MCV ∼100 fl) and a persistently
elevated fetal Hb (∼20–23%), while the platelet counts remained
in the low normal range. At the age of 7 yr, when presenting
with Mycoplasma pneumonia, there was severe epistaxis and
moderate thrombocytopenia (45,000 cells/µl), as well as platelet
function abnormalities that persisted even after the platelet
counts normalized. Platelet agglutination/aggregation was se-
verely impaired after stimulation with ristocetin, collagen, ADP,
and epinephrine. Severely decreased expression of CD62 and
CD63, respectively, were consistent with a α-granule and
δ-granule secretion defect. The family medical history was un-
remarkable with the exception of a maternal first cousin with a
chronic anemia of unclear etiology. When examined, the mother
Abdulhay et al. Journal of Experimental Medicine 1055
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was noted to have normal peripheral blood counts. Only limited
samples from the healthy mother could be obtained.
Patient 2 was a boy born to unrelated parents of African and
Asian ethnicity. The child was diagnosed antenatally with severe
anemia (Hb 2.4 g/dL) leading to hydrops fetalis, which was
treated with intrauterine transfusion at 22 wk gestation with
good response. The child was born by normal vaginal delivery at
40 wk gestation with no obvious dysmorphic features. The
family history was unremarkable with the exception of a ma-
ternal first cousin with thalassemia trait. The patient required
two further red cell transfusions at week 4 and week 8 of life for
anemia (Hb 6–7 g/dL with normal WBC and platelet counts).
Subsequently, he maintained a stable Hb of 8–10 g/dL and a
raised MCV (∼100 fl), with transient worsening of anemia as-
sociated with febrile illnesses. A bone marrow examination
performed at 18 mo of age showed normal cellularity with
mild trilineage dysplasia with signs of dyserythropoiesis and
small dysplastic megakaryocytes. Investigations performed
for hemolytic anemias, infections, and bone marrow failure
syndromes (diepoxybutane chromosome fragility test, RPS19
Figure 5. GATA1 variant shows complete loss of transcriptional activity. (A) Volcano plot showing log2 fold change (FC) of differentially expressed genes
between GATA1 wild type–infected and control cells at indicated P values. (B) Volcano plot showing log2 FC of differential genes between GATA1 mutant
infected and control cells at indicated P values. (C) Dot plot showing equivalent expression of GATA1 wild type and mutant based on RNA-seq for three
biological replicates per condition. cpm, counts per million. (D) RNA-seq coverage of the region containing the intron event showing GATA1wild-type cDNA and
GATA1mutant cDNA (biological replicate 1 for each condition shown). (E) Principal component plot of RNA-seq replicates (symbol) by condition (color) showing
PC1 and PC2 and the percent variance explained by each. This reveals that the GATA1 mutant clusters with the control, while the GATA1 wild type clusters
separately. (F) Heatmap showing clustering for the top genes (n = 232) differentially expressed between GATA1 wild type and empty HMD control (log2FC > 2,
p.adj < 0.01), which shows three distinct clusters. (G) Depiction of GATA1 chromatin occupancy in 60-bp bins in a 6-kb window surrounding the TSS for the
principal isoform of the indicated genes as in F shows an enrichment in cluster K1 genes. The darker red color in this plot indicates greater chromatin occupancy
by GATA1 in the G1E cells. For RNA-seq experiments, three biological replicates shown unless otherwise indicated.
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mutation analysis, MDS and juvenile myelomonocytic leukemia
mutation/cytogenetic screen) were unremarkable. He had
marginally elevated HbF (6.5%) and erythrocyte adenocyte
deaminase (123) levels. His platelet counts remained in the low
normal range with large platelets seen on the blood smear, and
because of a history of prolonged bleeding after circumcision
and recurrent mild epistaxis associated with respiratory in-
fections, platelet function tests were done at the age of 6 yr.
This showed abnormal platelet function with reduced aggre-
gation after stimulation with low-dose collagen (1 µg/ml) and
ADP (2 µM and 5 µM). ADP release was reduced on nucleotide
studies, hinting at a δ-granule secretion defect. A repeat bone
marrow examination done at the age of 7 yr because of falling
platelet counts (lowest 113,000 cells/µl) showed no new
changes. Subsequently his Hb and platelet counts have re-
mained stable at 9–10 g/dL and 115,000–160,000 cells/µl, re-
spectively. He remains clinically well with occasional mild
epistaxis and bruising after injury. The mother of the patient
had a reportedly normal peripheral blood count, but we were
unable to obtain samples from this individual for further study.
Study approval
All family members provided written informed consent to par-
ticipate in this study. The institutional review boards of Boston
Children’s Hospital, Massachusetts Institute of Technology, the
University ofMichigan, and the University of Freiburg approved
the study protocols.
Platelet aggregometry and flow cytometry
Platelet agglutination/aggregation were analyzed using the fol-
lowing agonists: ristocetin (1.2 mg/ml), collagen (2.0 µg/ml),
ADP (4.0 μmol/l), and epinephrine (8 μmol/l), as described
previously (Born and Cross, 1963). For flow cytometric analyses,
diluted platelet rich plasma (5 × 107 platelets/ml) was stimulated
with different concentrations of thrombin (0.025–1.0 U/ml) in
the presence of 1.25 mMGly-Pro-Arg-Pro. Platelets were stained
by monoclonal anti-CD62P (CLB-thromb/6-FITC) and anti-CD63
(CLB-gran/12-FITC) antibodies and analyzed by flow cytometry
as previously described (Lahav et al., 2002).
WES and related genetic analyses
The patients described in this paper are part of a rare blood
disorder cohort that has been studied through the use of WES.
WES was performed as previously described (Polfus et al., 2016;
Kim et al., 2017; Khajuria et al., 2018; Ulirsch et al., 2018).WES in
these cases was performed using genomic DNA obtained from
peripheral blood samples of the patients. The resultant variant
call file (in hg19 coordinates) was annotated with VEP v89
(McLaren et al., 2016) and rare variants (based on ExAC
v0.3.1 and GnomAD r2.0.2; Lek et al., 2016; http://gnomad.
broadinstitute.org/) were identified using a combination of the
Genome Analysis Toolkit, Bcftools, and Gemini (McKenna et al.,
2010; Li, 2011; Paila et al., 2013). No rare (<0.01% allele fre-
quency in ExAC and GnomAD) loss-of-function or missense
variants were identified in any known red blood cell disorder
genes (ANK1, SPTB, SPTA1, SLC4A1, EPB42, EPB41, PIEZO1, KCNN4,
GLUT1, G6PD, PKLR, NT5C3A, HK1, GPI, PGK1, ALDOA, TPI1, PFKM,
ALAS2, FECH, UROS, CDAN1, SEC23B, KIF23, KLF1, GATA1, HBB,
HBA1, HBA2, RPS7, RPS10, RPS15A, RPS17, RPS19, RPS20, RPS24,
RPS26, RPS27, RPS28, RPS29, RPS31, RPL5, RPL11, RPL15, RPL18,
RPL26, RPL27, RPL35, RPL35A, TSR2, and EPO), including those
known to cause dyserythropoietic anemia. We next expanded
our search to include all rare variants in these genes, and noted
chrX: 48,652,176 C>T in the fifth intron of GATA1 harbored by
these two patients, but absent from ExAC and GnomAD. The
variant was hemizygous in both patients and carried in both
mothers, suggesting a model of complete penetrance (the
mother of patient 1 was studied by exome sequencing, while the
mother of patient 2 had sequence analysis by Sanger sequenc-
ing). All mutations were confirmed from genomic DNA samples
of the patients or family members by Sanger sequencing.
Minigene assay and splicing analysis
The GATA1 region flanking exon 5 and exon 6 was PCR amplified
from genomic DNA from patient 1 and from a healthy unrelated
individual with the addition of XhoI and NotI restriction enzyme
sites (primers are as follows: GATA1 minigene forward, 59-ATC
ATCCTCGAGTCTTGGGTCCTCCTGACATC-39 and GATA1 mini-
gene reverse, 59-ATCATCGCGGCCGCCACATGGTCACACATT
GCAG-39) for cloning into the pSpliceExpress vector (Addgene;
Kishore et al., 2008). The constructs were transfected into hu-
man embryonic kidney 293T cells (ATCC) with FuGENE
(Promega). After reverse transcription of RNA obtained 48 h
after transfection using an RNAeasy Mini kit (Qiagen), RT-PCR
was performed, and amplified fragments were cloned using the
TOPO TA Kit (Thermo Fisher Scientific) to enable confirmation
of sequences through Sanger sequencing. For RT-PCR analyses,
the segment of interest in GATA1 was amplified with the fol-
lowing primers (GATA1 Exon 5, 59-AGTGGGGATCCCGTGTG-39
and GATA1 Exon 6, 59-ATCCTTCCGCATGGTCAGT-39). Am-
plified products were linearized with 1X TBE-Urea (Bio-Rad),
incubated for 10 min at 95°C, run on a 10% TBE-Urea Gel
(Bio-Rad), and subsequently visualized on a GelDoc instrument
(Bio-Rad) after 15 min of staining in ethidium bromide/1× TBE
buffer. For semiquantitative analyses, bands were quantified
from scanned images using ImageJ software (National Insti-
tutes of Health).
Cell culture and lentiviral transduction
Human primary adult bone marrow–derived CD34+ HSPCs were
obtained from Fred Hutchinson Cancer Research Institute and
cultured as previously described (Hu et al., 2013; Ludwig et al.,
2014). The wild-type or mutated (involving a five–amino acid
insertion corresponding with the observed intron retention
event) GATA1 cDNA constructs were cloned into the HMD
vector and transfected into 293T cells for lentiviral production,
along with helper plasmids, as described previously (Ludwig
et al., 2014). The primary HSPCs undergoing erythroid differ-
entiation were infected with lentiviruses on day 2 of differen-
tiation. Multiple donors were used in different experiments,
which all yielded similar results. On day 5 of differentiation,
cells were sorted for GFP and maintained in culture for further
terminal erythroid differentiation (Ulirsch et al., 2016). Differ-
entiating cells were collected on days 7, 9, and 12 for flow
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cytometric analysis with erythroid markers CD235a (HIR2; BD
Biosciences), CD71 (OKT9; Invitrogen), and CD49d (9F10 or
MZ18-24A9; BioLegend; Miltenyi) using a Fortessa Instrument
(BD Biosciences). Cells were gated on live events using PI. G1E
cells were kindly provided by the laboratory of Dr. Mitchell
Weiss (St. Jude Children's Research Hospital, Memphis, TN) and
cultured with 15% FBS, 1-thiogycerol, murine stem cell factor
(Peprotech), and human erythropoietin (Amgen). G1E cells were
infected with the lentiviruses discussed above and were either
subjected to flow cytometric analysis with the mouse erythroid
marker Ter119 and GFP using an Accuri cytometer (BD Bio-
sciences) or sorted and subjected to downstream analyses.
Lentiviruses expressing SF3B1 wild-type or K700E mutants, as
described (Obeng et al., 2016), were used to infect 293T cells 1 d
before transfection, as above for the minigene assay. Cytocen-
trifugation was performed with ∼100,000–200,000 cells using
a Shandon Cytospin 4 onto polylysine-coated slides at 300× RPM
for 4 min. After drying, samples were stained with May-
Grünwald for 5 min and then with Giemsa for 15 min, as pre-
viously described (Fiorini et al., 2017). Images were taken using
a Nikon Eclipse E800microscope and Nikon Elements Software.
Western blotting
Approximately 1 million G1E cells were collected 72 h after
infection and lysed in radioimmunoprecipitation assay buffer
supplemented with protease and phosphatase inhibitor cock-
tails (Santa Cruz). Proteins were quantified according to the DC
Protein assay (Bio-Rad), run using a Mini-Protean TGX gel
system (Bio-Rad) and transferred onto a polyvinylidene fluo-
ride membrane. Signal was detected by ECL Amersham Hy-
perfilm (GE Healthcare). Western blotting was performed
using GATA1 (M20) and GAPDH (6C5) primary antibodies at 1:
1,000 dilution (Santa Cruz). An HRP-conjugated goat anti-
mouse was used at 1:20,000 dilution as a secondary antibody
(Bio-Rad). For the 293T cells, a GAPDH antibody (0411; Santa
Cruz) was used.
G1E RNA-seq
Cells were lysed in RLT lysis buffer (Qiagen) supplemented with
β-mercaptoethanol, and RNA was isolated using a RNeasy Mini
Plus kit (Qiagen) according to the manufacturer’s instructions.
RNA was quantified using NanoDrop OneC (Thermo Fisher
Scientific). 30 ng of RNA was used as input to a modified
SMART-seq2 (Picelli et al., 2014) protocol, and after reverse
transcription, eight cycles of PCR were used to amplify the
transcriptome library. The quality of whole-transcriptome li-
braries was validated using a High Sensitivity DNA Chip run on
a Bioanalyzer 2100 system (Agilent), followed by library prep-
aration using the Nextera XT kit (Illumina) and custom index
primers according to the manufacturer’s instructions. Final li-
braries were quantified using a Qubit dsDNA HS Assay kit (In-
vitrogen) and a High Sensitivity DNA chip run on a Bioanalyzer
2100 system.
Sequencing
All libraries were sequenced using Nextseq High Output Car-
tridge kits and a Nextseq 500 sequencer (Illumina). Libraries
were consistently sequenced paired end (2 × 38 bp) and de-
multiplexed using the bcl2fastq program.
Alignment and differential expression
For each library, raw fastq reads were aligned using STAR
version 2.5.1b (RNA-seq; Dobin et al., 2013) using the 2-Pass
mode to the GRCm38.p4 reference genome, and gene expres-
sion counts were generated using quantMode in STAR. Human
GATA1 cDNA (wild type and mutant) in the HMD vector, as
described above, were appended as an additional chromosome.
Differential expression was performed using the DEseq2method
(Love et al., 2014), and gene-wise statistical significance was
determined using independent hypothesis weighting of 0.01
(Ignatiadis et al., 2016).
Clustering
A consistent set of features for the RNA-seq data were estab-
lished by choosing the top differentially expressed genes be-
tween control (HMD) and GATA1 wild-type G1E cells (p.adj <
0.01, log2FC > 2, n = 223). A top genes by sample matrix of
log2CPM values was created and transformed to Z scores. The
optimal cluster number (3) was determined by NbClust, com-
puted by K-means with three centers, and Z scores were plotted
using ComplexHeatmap R package (Gu et al., 2016).
Principal components analysis
Principal components of the G1E RNA-seq experiment were
computed using the rlog transformation of the gene count ma-
trix and plotted using the plotPCA function of the DESeq2
package.
ChIP-seq analysis
ChIP-seq data were obtained from the NCBI Gene Expression
Omnibus (GEO; accession no. GSE36029) and aligned using
Bowtie2 version 2.3.3 (Langmead and Salzberg, 2012). The 30-h
17β-estradiol–treated G1E-ER4 cell sample (GSM995448) was
used, as it is most representative of our experiment. The GATA1
binding profiles were determined for the top genes determined
in the clustering analysis in a ±3-kb window around the ca-
nonical isoform TSSs, and Z scores were plotted as a heatmap
using Complex Heatmap.
Human erythropoiesis RNA-seq analysis
Single-end RNA-seq datasets for five distinct maturation stages
of primary human erythroid cells in biological triplicates were
obtained from the NCBI GEO database (accession no. GSE53983;
An et al., 2014). These datasets were aligned to the Ensembl
GRCh37 r75 genome and gene annotations using 2-Pass STAR
alignment. Resultant alignments were imported into R and vi-
sualized with Gviz.
Analysis of MDS patient samples
Cryopreserved bone marrow mononuclear cells from MDS pa-
tients with refractory anemia with ringed sideroblasts and
healthy controls were thawed, washed, and recovered before
staining with fluorescently conjugated antibodies targeting
CD235a (HIR2), CD71 (OKT9), and CD34 (4H11). SF3B1 mutations
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had been analyzed and confirmed in other investigations on
these samples but were not specifically done for this study. Flow
cytometric cell sorting for CD235a+CD71+ and CD34+ was per-
formed using a FACSAria II Cell Sorter (BD Biosciences). After
sorting, the cells were washed, and RNA was isolated using the
Ambion small RNA extraction kit (Zymo). cDNA was synthe-
sized from the recovered RNA samples (20–40 ng) using the
iScript cDNA Kit (Bio-Rad). RT-PCR was performed with GATA1
primers and normalization controls (primers GATA1 Exon 5, 59-
AGTGGGGATCCCGTGTG-39, GATA1 Exon 6, 59-ATCCTTCCGCAT
GGTCAGT-39, GAPDH Exon 3, 59-CACCAGGGCTGCTTTTAACT-
39, and GAPDH Exon 4, 59-GACAAGCTTCCCGTTCTCAG-39).
Bands were visualized on denaturing gels and quantified as
noted above. Samples were also analyzed with quantitative RT-
PCR for GATA1 using a CFX96 Real Time Thermocycler (Bio-
Rad) with SYBR Green (Bio-Rad; primers GATA1 Exon 2, 59-CCC
CAGTTTGTGGATCCT-39 and GATA1 Exon 3, 59-CACAGTTGA
GGCAGGGTAGAG-39, human ACTB Exon 3, 59-AGAAAATCTGGC
ACCACACC-39, and human ACTB Exon 4, 59-GGGGTGTTGAAG
GTCTCAAA-39).
Statistical analysis
All pairwise comparisons were performed using the two-tailed
Student’s t test, unless otherwise indicated. Differences were
considered significant if the P value was <0.05.
Data availability
The WES data are available in the dbGaP database (http://www.
ncbi.nlm.nih.gov/gap) under the accession no. phs000474.
RNA-seq data are available in the GEO database (https://www.
ncbi.nlm.nih.gov/geo/) under accession no. GSE124830.
Online supplemental material
Fig. S1 shows clinical phenotypes and WES data for affected
patients. Fig. S2 shows the GATA1 mRNA levels of SF3B1 MDS
patients in sorted marrow populations. Fig. S3 shows cytocen-
trifuge analysis of G1E cells expressing wild-type or mutated
GATA1.
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